论文部分内容阅读
目的:观察和比较托吡酯、卡马西平与丙戊酸钠对治疗脑炎继发癫痫的临床疗效及安全性。方法:选择2013年1月~2015年9月在我院进行诊治的脑炎继发癫痫患者80例,随机分为托吡酯组、卡马西平组和丙戊酸钠组,分别采用托吡酯、卡马西平与丙戊酸钠治疗,比较三组的治疗有效率、执行能力与视空间、命名、抽象、注意、定向、语言以及延迟回忆等认知功能评分及不良反应的发生情况。结果:托吡酯组的有效率最高,为80.65%(25/31),卡马西平组的有效率最低,为70.00%(21/30),但三组间有效率相比差异无统计学意义(P>0.05)。治疗后,托吡酯组患者的执行能力与视空间、命名、抽象、注意、定向、语言以及延迟回忆等认知功能评分均明显高于卡马西平组和丙戊酸钠组(P<0.05);托吡酯组的不良反应发生率(12.90%)明显低于卡马西平组(36.67%)和丙戊酸钠组的(29.62%)(P<0.05)。结论:托吡酯、卡马西平以及丙戊酸钠治疗脑炎继发癫痫疗效相当,但托吡酯对患者认知功能损害最小,安全性最高。
Objective: To observe and compare the clinical efficacy and safety of topiramate, carbamazepine and sodium valproate in the treatment of secondary epilepsy with encephalitis. Methods: Eighty patients with epilepsy secondary to encephalitis who were diagnosed and treated in our hospital from January 2013 to September 2015 were randomly divided into topiramate group, carbamazepine group and sodium valproate group. Topiramate, Xiping and sodium valproate treatment, treatment efficiency, executive ability and visual function, naming, abstraction, attention, orientation, language and delayed recall and other cognitive function scores and adverse reactions were compared. Results: Topiramate had the highest effective rate (80.65%, 25/31) and carbamazepine (70.00%, 21/30), but there was no significant difference between the three groups P> 0.05). After treatment, the cognitive ability scores of patients in topiramate group were significantly higher than those in carbamazepine group and sodium valproate group (P <0.05). The scores of cognitive ability in view, space, naming, abstraction, attention, orientation, The adverse reaction rate (12.90%) in topiramate group was significantly lower than that in carbamazepine group (36.67%) and sodium valproate group (29.62%) (P <0.05). Conclusion: Topiramate, carbamazepine and sodium valproate are effective in treating epilepsy secondary to encephalitis, but topiramate has the lowest cognitive impairment and the highest safety.